Danielle P. Meyrick
Perth, WA 6009, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
First-in-Human 212Pb-PSMA-Targeted α-Therapy SPECT/CT Imaging in a Patient with Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 01, 2023
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.
Journal: Diagnostics (Basel, Switzerland)
Published: March 02, 2021
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Journal: Targeted oncology
Published: February 10, 2021
Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer.
Journal: World journal of nuclear medicine
Published: September 14, 2019
Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer.
Journal: Clinical kidney journal
Published: April 26, 2019
Preparation of starch-based porous carbon electrode and biopolymer electrolyte for all solid-state electric double layer capacitor.
Journal: Journal of colloid and interface science
Published: April 22, 2019
177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.
Journal: Oncotarget
Published: December 27, 2018
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: July 11, 2018
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer.
Journal: Diagnostics (Basel, Switzerland)
Published: December 12, 2017
The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
Journal: Nuclear medicine communications
Published: September 19, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026